A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of DW1809-T2

NCT05214690 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2022-01-31

No results posted yet for this study

Summary

Randomized, Open-label, Oral, Single-dose, two-Sequence, four-Period, crossover study

Conditions

Interventions

DRUG

DW1809-T2

pelubiprofen 25mg

DRUG

DW1809-1

pelubiprofen 30mg (PELUBI tab.)

Sponsors & Collaborators

  • Daewon Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-08-13
Primary Completion
2020-09-08
Completion
2020-09-08

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05214690 on ClinicalTrials.gov